Cognitive Behavioral Therapy Improves Insomnia in Patients with Cancer
the Cancer Therapy Advisor take:
According to a new study published in the Journal of Clinical Oncology, cognitive behavioral therapy for insomnia significantly improves sleep quality and insomnia in patients with cancer, while armodafinil, a wakefulness-promoting agent, did not.
For the study, researchers sought to investigate the use of cognitive behavioral therapy for insomnia plus armodafinil would result in improved insomnia control in cancer survivors compared with cognitive behavioral therapy alone. The researchers enrolled 96 cancer survivors with an average age of 56 years.
Of those, 87.5% were female and 68% had breast cancer. Participants were randomly assigned to receive cognitive behavioral therapy for insomnia plus armodafinil or placebo, armodafinil alone, or placebo alone. Each intervention was administered for 7 weeks.
Results showed that both cognitive behavioral therapy for insomnia plus armodafinil (P = 0.001) and cognitive behavioral therapy plus placebo (P = 0.010) significantly reduced the severity of insomnia compared with placebo alone. Similar results were observed in regard to sleep quality and improvements in both areas continued 3 months following treatment. However, behavioral therapy plus armodafinil was not significantly better than behavioral therapy plus placebo (P = 0.421). Armodafinil alone was not significant better than placebo alone (P = 0.584). The findings suggest that cognitive behavioral therapy for insomnia alone improved the severity of insomnia and sleep quality the most.
Cognitive behavioral therapy for insomnia significantly improves sleep quality and insomnia in patients with cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Opinion: Understanding the FDA's Take on Cannabidiol
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk